UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S180-S181

2016

Volltextzugriff (PDF)

P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia

European neuropsychopharmacology, 2015-09, Vol.25, p.S473-S474

2015

Volltextzugriff (PDF)

P.1.f.004 Immunomodulating effects of classical and atypical antipsychotics

European neuropsychopharmacology, 2014-10, Vol.24, p.S196-S197

2014

Volltextzugriff (PDF)

P.1.g.066 Proteolytic hydrolysis of myelin basic protein by IgGs during long-term treatment of schizophrenia

European neuropsychopharmacology, 2015-09, Vol.25, p.S272-S273

2015

Volltextzugriff (PDF)

Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S512-S513

2016

Volltextzugriff (PDF)

P.3.e.004 Abzymes with catalase-like activity of patients with schizophrenia after treatment with haloperidol

European neuropsychopharmacology, 2014-10, Vol.24, p.S565-S566

2014

Volltextzugriff (PDF)

P.3.c.032 Spectrum of middle-mass endotoxic molecules and antibodies to DNA in schizophrenia patients with tardive dyskinesia

European neuropsychopharmacology, 2011, Vol.21, p.S486-S487

2011

Volltextzugriff (PDF)

P.3.a.006 Tardive dyskinesia, dehydroepiandrosterone sulfate and cytochrome P450c17α gene polymorphism in psychiatric inpatients

European neuropsychopharmacology, 2014-10, Vol.24, p.S486-S487

2014

Volltextzugriff (PDF)

P.3.c.039 Effects of neuroleptic treatment on oxidative stress parameters in schizophrenia patients

European neuropsychopharmacology, 2010, Vol.20, p.S480-S481

2010

Volltextzugriff (PDF)

P.3.005 Tardive dyskinesia and polymorphisms of the phosphatidylinositol-4-phosphate 5-kinase IIa gene in Russian schizophrenic patients

European neuropsychopharmacology, 2012-03, Vol.22, p.S56-S56

2012

Volltextzugriff (PDF)

P.3.d.01l The immunomodulatory effects of atypical neuroleptics quetiapine and amisulpride in the dynamics of 6-week treatment

European neuropsychopharmacology, 2009, Vol.19, p.S560-S560

2009

Volltextzugriff (PDF)

P.3.c.042 Tardive dyskinesia and cytochrome P450 1A2 gene polymorphism in Russian patients with schizophrenia

European neuropsychopharmacology, 2011, Vol.21, p.S492-S493

2011

Volltextzugriff (PDF)

P.3.d.011 Immunotropic effects of atypical neuroleptics olanzapine and amisulpride

European neuropsychopharmacology, 2008, Vol.18, p.S454-S455

2008

Volltextzugriff (PDF)

Immune parameters and aminotransferase blood serum level in dynamics of atypical neuroleptics treatment of schizophrenic patients

European psychiatry, 2008-04, Vol.23, p.S128-S128

2008

Volltextzugriff (PDF)

P.3.c.017 Influence of atypical neuroleptic quetiapine on the serum dehydroepiandrosterone/ cortisol ratio in schizophrenia

European neuropsychopharmacology, 2007, Vol.17, p.S433-S434

2007

Volltextzugriff (PDF)

P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients

European neuropsychopharmacology, 2010, Vol.20, p.S486-S487

2010

Volltextzugriff (PDF)

P.1.a.031 - Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S180-S181

2016

Volltextzugriff (PDF)

Assessment of the myelination of brain structures in patients with schizophrenia using the MRI method

European neuropsychopharmacology, 2017-10, Vol.27, p.S712-S713

2017

Volltextzugriff (PDF)

P.1.i.034 - Assessment of the myelination of brain structures in patients with schizophrenia using the MRI method

European neuropsychopharmacology, 2017-10, Vol.27, p.S712-S713

2017

Volltextzugriff (PDF)

Morphophenotypical patterns in patients with negative symptoms in schizophrenia

European psychiatry, 2017-04, Vol.41 (S1), p.S818-S818

2017

Volltextzugriff (PDF)

P.3.b.032 - Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia

European neuropsychopharmacology, 2016-10, Vol.26, p.S512-S513

2016

Volltextzugriff (PDF)

P.3.d.043 - Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia

European neuropsychopharmacology, 2017-10, Vol.27, p.S956-S956

2017

Volltextzugriff (PDF)

Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia

European neuropsychopharmacology, 2017-10, Vol.27, p.S956

2017

Volltextzugriff (PDF)

Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy

Bulletin of experimental biology and medicine, 2015-12, Vol.160 (2), p.283-285

2015

Volltextzugriff (PDF)

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects

Bulletin of experimental biology and medicine, 2016-03, Vol.160 (5), p.687-690

2016

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Internal Medicine
(20)
Psychiatry
(18)
Schizophrenia
(3)
Science & Technology
(3)
Antipsychotic Agents
(2)
Biomedical And Life Sciences
(2)
Biomedicine
(2)
Cell Biology
(2)
Female
(2)
Humans
(2)
Laboratory Medicine
(2)
Life Sciences & Biomedicine
(2)
Male
(2)
Medicine, Research & Experimental
(2)
Pathology
(2)
Research & Experimental Medicine
(2)
Schizophrenia - Drug Therapy
(2)
Adult
(1)
Antioxidants
(1)
Antipsychotic Agents - Adverse Effects
(1)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia

P.3.b.018 Gene polymorphisms of oxidative stress and glutamatergic system in schizophrenic patients with tardive dyskinesia

P.1.f.004 Immunomodulating effects of classical and atypical antipsychotics

P.1.g.066 Proteolytic hydrolysis of myelin basic protein by IgGs during long-term treatment of schizophrenia

Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia

P.3.e.004 Abzymes with catalase-like activity of patients with schizophrenia after treatment with haloperidol

P.3.c.032 Spectrum of middle-mass endotoxic molecules and antibodies to DNA in schizophrenia patients with tardive dyskinesia

P.3.a.006 Tardive dyskinesia, dehydroepiandrosterone sulfate and cytochrome P450c17α gene polymorphism in psychiatric inpatients

P.3.c.039 Effects of neuroleptic treatment on oxidative stress parameters in schizophrenia patients

P.3.005 Tardive dyskinesia and polymorphisms of the phosphatidylinositol-4-phosphate 5-kinase IIa gene in Russian schizophrenic patients

P.3.d.01l The immunomodulatory effects of atypical neuroleptics quetiapine and amisulpride in the dynamics of 6-week treatment

P.3.c.042 Tardive dyskinesia and cytochrome P450 1A2 gene polymorphism in Russian patients with schizophrenia

P.3.d.011 Immunotropic effects of atypical neuroleptics olanzapine and amisulpride

Immune parameters and aminotransferase blood serum level in dynamics of atypical neuroleptics treatment of schizophrenic patients

P.3.c.017 Influence of atypical neuroleptic quetiapine on the serum dehydroepiandrosterone/ cortisol ratio in schizophrenia

P.3.c.050 Interaction between polymorphisms of oxidative enzymes and susceptibility to tardive dyskinesia in psychiatric patients

P.1.a.031 - Association of PIP5K2A and SGK1 genes with drug-induced dyskinesia in patients with schizophrenia

Assessment of the myelination of brain structures in patients with schizophrenia using the MRI method

P.1.i.034 - Assessment of the myelination of brain structures in patients with schizophrenia using the MRI method

Morphophenotypical patterns in patients with negative symptoms in schizophrenia

P.3.b.032 - Gene polymorphisms of cytochrome P450, 1A2, 2D6 and drug-induced tardive dyskinesia in Russian patients with schizophrenia

P.3.d.043 - Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia

Association between P-glycoprotein polymorphisms and antipsychotic drug-induced hyperprolactinemia

Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects

Suchergebnisse filtern